1. Introduction {#sec1}
===============

A timely diagnosis of dementia is considered of major importance to ensure adequate access to information, evidence-based treatment, care, and support for people with dementia [@bib1]. However, even in high-income countries with advanced medical care systems, 50% to 80% of all prevalent dementia cases are not formally diagnosed [@bib1], [@bib2], [@bib3]. The screening of older patients for cognitive impairment could be a method to improve the recognition of dementia. Previous studies have shown that screening for dementia in general practitioners\' (GPs) practices did increase the diagnosis rates [@bib4], [@bib5]. Nevertheless, routine screening for dementia has been controversial and is not presently recommended in the dementia guidelines owing to the lack of evidence that patients benefit from it [@bib6], [@bib7], [@bib8]. In addition, patients with positive screening results often undergo no additional diagnostic assessment and do not receive specific treatment [@bib4], [@bib5]. For the benefit of patients, a positive screening outcome should initiate an adequate diagnostic assessment and, depending on the results, state of the art treatment and care. Furthermore, screening could result in potential harms [@bib9], [@bib10], [@bib11], [@bib12]. Older patients might avoid visiting their GP because they fear to be diagnosed with dementia. Also, false-positive screening results increase the probability for misdiagnosis, could result in unnecessary examinations and treatments, and might cause anxiety and depression in the affected subjects. Boustani et al [@bib13] showed that the probability of false-positive screening results is relatively high: about 20% of patients who screened positive for dementia did not have dementia at all and another 30% had mild cognitive impairment. Sandholzer et al [@bib5] examined the acceptance of screening among German primary care patients and found that 89% of the screened patients considered the screening to be useful. Only 1.5% of the patients reported that they worried more about their health after the screening. Other surveys revealed that a clear majority of participants would prefer to be diagnosed early and expected to be properly informed about their diagnosis [@bib14], [@bib15].

Initiatives have been implemented to improve the recognition of dementia, such as the "Annual Wellness Visit" for Medicare enrollees in the United States that includes the detection of any cognitive impairment [@bib16]. Also, the proactive "dementia case finding scheme" was initiated by the government of the United Kingdom, aiming to increase the diagnosis rate of dementia and to improve dementia treatment and care on the population level [@bib17]. No recent data are available about the effect that screening for dementia would have on the diagnostic process in German primary care practice. Thus, the present research report aims to contribute empirical findings to (1) the effect of a screening test for dementia in German primary care practices on the rate of a formal diagnosis of dementia; (2) the distribution of etiologies of newly assigned diagnoses after a screening for dementia; and (3) the factors associated with receiving a formal diagnosis of dementia after a positive dementia screening test.

2. Methods {#sec2}
==========

2.1. Study design {#sec2.1}
-----------------

The present cross-sectional analyses were performed on data derived from the ongoing GP-based, randomized, controlled intervention trial, Dementia: life- and person-centered help in Mecklenburg-Western Pomerania (DelpHi-MV). The details of the study have been previously reported [@bib18]. The eligible patients (aged \>70 years and living at home) were screened for dementia at participating GP practices using DemTect [@bib19]. This personal interview-based instrument includes five tasks (recall of a word list, number transcoding task, word fluency task, digit span reverse, delayed recall of word list) and is widely used for dementia screening in general practices in Germany [@bib20]. The patients who meet the inclusion criteria for the DelpHi trial (DemTect score \<9) were informed by their GPs about the study, invited to participate, and asked to provide written informed consent. If the patient named a caregiver, the caregiver was asked to participate in the study. When patients were unable to give written informed consent, their legal representative was asked to sign the consent form on their behalf (as approved by the Ethical Committee of the Chamber of Physicians of Mecklenburg-Western Pomerania, registry number BB 20/11). The study physicians received allowances for performing the screening test (10€ per patient) and study enrollment (100€ per patient).

Study enrollment into the main study began January 1, 2012. The participants and their caregivers were assigned to an intervention or a control group, depending on whether the treating GP practice had been randomized to the control or intervention group. In both groups, identical, standardized, computer-assisted baseline assessments were conducted as face-to-face interviews at the participants\' homes. After the baseline assessment, the intervention group received the "DelpHi-Intervention" (for a detailed description of the DelpHi-Intervention, see Eichler et al [@bib21]). In contrast, the control group received "care as usual." The [ClinicalTrials.gov](http://ClinicalTrials.gov){#intref0010} identifier is [NCT01401582](ctgov:NCT01401582){#intref0015}.

2.2. Study population {#sec2.2}
---------------------

A total of 4064 patients were screened for dementia in 108 participating GP practices. Of these, 692 patients (17%) were eligible for the DelpHi trial, and 406 patients (59%) agreed to participate in the study. However, 90 participants either did not start the baseline assessment or had not finished all parts of the assessment at the time of the analyses.

Fifty-eight patients were withdrawn from the analyses owing to withdrawal of informed consent (n = 31), death (n = 20), relocation (n = 3) or other reasons (n = 4). No statistically significant differences were found between the patients included in the analyses and those who withdrew for DemTect score, age, and sex (see [Supplemental Table 1](#appsec1){ref-type="sec"}, available online).

Fifteen patients were excluded because the psychometric instruments could not be used (the patients were unable to answer the questions because of the severity of dementia or the patients had refused to answer for other reasons). The patients included in the analyses had significantly higher DemTect scores than those patients excluded because of missing data (mean 5.84 ± 2.02 versus 3.73 ± 2.34; Welch\'s *t* test, t(15.50) = 3.41; *P* \< .01). Regarding age, sex, and a formal diagnosis of dementia, we found no significant differences (see [Supplemental Table 2](#appsec1){ref-type="sec"}, available online).

The complete baseline assessment regarding relevant variables was available for 243 patients (January 1, 2014, preliminary data). Of the 243 patients, 97 (40%) had been formally diagnosed with dementia by their GP before the screening (53% unspecified dementia; 24% vascular dementia; 19% Alzheimer\'s disease). Patients with a formal diagnosis had a significantly lower score on the DemTect (mean 5.43 ± 2.09 versus 6.11 ± 1.94; Welch\'s *t* test, t(196.42) = 2.57, *P* = .01) and the Mini Mental State Examination (MMSE) [@bib22] than patients not previously diagnosed with dementia (mean 20.34 ± 5.88 versus 23.12 ± 4.96; Welch\'s *t* test, t(181.49) = 3.84, *P* \< .001). A detailed comparison of the patients with and without a formal diagnosis of dementia before screening can be found in the study by Eichler et al [@bib3]. The presented analyses were based on data from 146 patients without a formal diagnosis of dementia before screening.

2.3. Procedures and instruments {#sec2.3}
-------------------------------

For the sample description, patient age, sex, living situation (alone versus not alone), cognitive status, depression, and functional status were analyzed. Cognitive status was assessed using the German version of the MMSE [@bib22]. In the analyses, we used the total MMSE score and a categorization indicating "no cognitive impairment" (score 27--30), "mild" (score 20--26), "moderate" (score 10--19), and "severe cognitive impairment" (score 0--9). Depression was operationalized using the score of the Geriatric Depression Scale [@bib23], [@bib24] as a dichotomized variable ("no depression," score 0--5; "depression," score 6--15). The functional status was assessed using the Bayer Activities of Daily Living Scale [@bib25], [@bib26], which yields a mean score of 1 to 10, where 1 indicates the lowest possible impairment and 10 the highest possible impairment. For all patients who had provided the respective informed consent, the formal medical diagnoses (International Classification of Disease, version 10, codes F00, F01, F02, F03, G30, and G31) were retrieved from the medical records in the GP practice (including the exact date of the initial diagnosis).

2.4. Statistical analysis {#sec2.4}
-------------------------

We summarized the variables that describe the sample using descriptive statistics. To assess the effect of screening on the formal diagnosis rate, we categorized the patients into two groups: patients diagnosed after screening (all patients who had received a formal diagnosis of dementia between the day of screening and the baseline assessment) and patients not diagnosed after screening (all patients who had not received a formal diagnosis between the day of screening and the baseline assessment). To test for the differences between those groups, we used Welch\'s *t* test (robust to unequal variances) for continuous and Fisher\'s exact test for categorized variables. To identify the factors associated with the assignment of a diagnosis of dementia after screening, we fitted a logistic regression model, including age, sex, living situation, cognitive impairment, depression, and functional status. Because DelpHi-MV is a cluster-randomized trial, the dependency of data from participants who belonged to the same cluster (i.e., the same treating GP) had to be considered. Therefore, we applied a conditional (fixed effect) logistic regression model, which offers consistent estimates in cases of clustered data [@bib27], [@bib28]. Before running the final regression model, we checked for nonlinear relations using the multivariate fractional polynomial procedure [@bib29]. We found no indication for nonlinear relations; thus, these predictors were included in linear terms. The chosen estimation procedure excluded 60 observations because of the invariance in the outcome variable in certain clusters (i.e., all or none of the patients treated by the same GP were formally diagnosed with dementia). We found no significant differences between the included and these excluded cases regarding the analyzed variables (see [Supplemental Table 3](#appsec1){ref-type="sec"}, available online). The final regression analysis was performed on the remaining 86 patients assigned to 15 clusters (the clusters were unbalanced). Standard errors of the regression coefficients were estimated using the jackknife method, which allows one to estimate standard errors in complex samples [@bib30]. Statistical analyses were performed using Stata/IC [@bib31].

3. Results {#sec3}
==========

3.1. Sociodemographic and clinical characteristics {#sec3.1}
--------------------------------------------------

The sociodemographic and clinical characteristic of the study sample are listed in [Table 1](#tbl1){ref-type="table"}.

3.2. Effect of screening on receiving a formal diagnosis {#sec3.2}
--------------------------------------------------------

Of 146 patients who had not been formally diagnosed before screening, 72 (49%) received at least one formal diagnosis of dementia after a positive DemTect screening. Of these, 38 (53%) received the formal diagnosis on the day of the screening.

3.3. Distribution of differential diagnoses {#sec3.3}
-------------------------------------------

The distribution of newly assigned differential diagnoses after screening is shown in [Figure 1](#fig1){ref-type="fig"}. "Unspecified dementia" was by far the most often assigned diagnosis; 69% of the patients received this diagnosis. This proportion was still higher in the patients who received their diagnosis at the day of screening (74%).

3.4. Factors associated with receiving a formal diagnosis of dementia after positive DemTect screening {#sec3.4}
------------------------------------------------------------------------------------------------------

Univariate statistical analyses revealed that patients who had received a formal diagnosis of dementia after screening were significantly more often women (74% versus 51%) and were significantly more often severely impaired regarding their cognitive (MMSE) and functional status (Bayer Activities of Daily Living Scale; [Table 1](#tbl1){ref-type="table"}).

In the multivariate conditional logistic regression analyses, the only factor significantly associated with receiving a formal diagnosis of dementia after screening was female sex \[F(6,14) = 3.68, *P* \< .05\]. The chance of receiving a formal diagnosis after a positive DemTect screening was more than five times greater for women than for men (odds ratio 5.42; *P* \< .01; 95% confidence interval 1.93--15.22). The results are listed in [Table 2](#tbl2){ref-type="table"}.

4. Discussion {#sec4}
=============

The present analysis revealed a strong effect of screening for dementia among German primary care patients on the probability of receiving a formal diagnosis of dementia. Almost 50% of previously undiagnosed patients received a formal diagnosis of dementia after they had screened positive at their GP practice. The overall diagnosis rate in primary care patients who had screened positive for dementia increased from 40% before screening [@bib3] to 70% after screening. Thus, our findings indicate that a considerable number of patients with cognitive impairment might not be recognized by their GP without a cognitive test. The results of the multivariate analysis showed that the chance of receiving a formal diagnosis after a positive DemTect screening was more than five times higher in woman than in men; thus, women, in particular, might benefit from screening.

Previous research has demonstrated that physicians often do not recognize cognitive impairment, even in those with severe dementia [@bib1], [@bib13], [@bib32], [@bib33]. For German primary care patients, Sandholzer et al [@bib5] showed that the prevalence of cognitive impairment in patients aged 70 years or older was 4.6% according to the GP diagnosis but 21% according to the MMSE score.

Our results have provided evidence that routine screening can improve the identification of dementia considerably. To the best of our knowledge, this study is the first to demonstrate such a profound effect of screening, although previous studies reported substantially smaller effects. Sandholzer et al [@bib5] found that only 6% of the German primary care patients who had screened positive for dementia had received any diagnostic assessment or treatment. Borson et al [@bib4] showed that relevant physician behavior (i.e., a formal diagnosis of dementia, specialist referral, or cognitive enhancing medication) occurred for only 17% of the positively screened patients. A reason for the considerably high effect of screening in the present study could have been the active involvement of the participating GPs in a dementia intervention trial that aimed to optimize treatment and care for people with dementia. The GPs did not only receive information about the result of the cognitive test. Furthermore, they informed all positively screened patients about the DelpHi trial and had obtained their informed consent for study participation. This might have increased the perceived importance of a positive screening outcome, which could have led to an increased probability that the respective patients would receive a formal diagnosis of dementia. This might have been a sort of clinical "Hawthorne effect" such that the GPs might have changed their behavior because they were participating in an intervention study [@bib34], [@bib35].

According to the medical files of the participating GP practices, more than 50% of the newly diagnosed patients received their formal diagnosis on the day of the screening. In addition, the proportion of the diagnosis of "unspecified dementia" as the only diagnosis was considerably high (69% of all patients formally diagnosed after screening and 74% of patients formally diagnosed at the day of screening). This could imply that some GPs might assign a formal diagnosis to patients because of a positive screening result. However, our data did not provide any insight into the process of assigning a formal diagnosis. A desired consequence would be that a positive screening result would initiate additional differential diagnostic assessments of the patients. Without an adequate diagnostic assessment, the risk of assigning a false-positive diagnosis of dementia is high [@bib13]. Reversible causes of cognitive impairment, such as depression, vitamin B~12~ deficiency, or hypothyroidism might remain unrecognized and therefore untreated.

In the present sample, 24% of the patients who screened positive for dementia on the DemTect (score \<9) received a formal diagnosis of dementia but were not cognitively impaired according to their MMSE result (score 27--30; assessed at baseline). Some of these patients might have been misdiagnosed. Because previous studies showed that the MMSE is less sensitive for detecting milder forms of cognitive impairment (43%--43%) [@bib36] than the DemTect (80%--100%) [@bib19], [@bib37], the rate of false-positive diagnoses in our study might have been lower than 24%. However, we were unable to validate the GP diagnoses with our data. Nevertheless, analyzing our follow-up data will allow more detailed information about which formal diagnosis will be confirmed or changed in the course of the disease and what processes of additional differential diagnostic and treatment will be followed after the initial diagnosis.

The potential adverse effects of a false-positive diagnosis must be weighed against the harm of overlooking dementia. Recognizing and diagnosing dementia is an inevitable prerequisite for providing adequate information, treatment, and care. Thus, although screening for dementia in elderly patients has not yet been adopted in the dementia guidelines [@bib6], [@bib7], [@bib8], it could be a possibility to reduce the high rates of unrecognized dementia. The requirements for an adequate procedure to detect cognitive impairment in routine care are currently being discussed. The Alzheimer\'s Association has proposed an algorithm to detect cognitive impairment during the Medicare "Annual Wellness Visit" in a primary care setting in the United States [@bib16] that could also be a possible strategy for primary care settings in other countries. Because screening entails the risk that patients will receive a false-positive diagnosis of dementia after they have screened positive, additional diagnostic assessments should be mandatory. Also, the proactive provision of adequate treatment and care in the case of a confirmed diagnosis should be fostered.

Currently, little evidence is available that shows improved health outcomes for patients who have been formally diagnosed with dementia [@bib9], [@bib38]. Regarding the potential adverse effects of screening, no studies have yet directly addressed the adverse psychological effects of screening or the adverse effects of false-positive test results [@bib38]. Thus, the potential positive and negative consequences of screening for dementia require systematic and comprehensive evaluation. Analyzing our follow-up data will enable us to provide additional evidence. In the DelpHi trial [@bib18], [@bib21], the patient outcomes of the control group receiving "care as usual" will be compared with the outcomes of the intervention group receiving a collaborative dementia care management after screening positive for dementia. Thus, we will be able to determine the effect of receiving a formal diagnosis of dementia after a positive screening result on various outcomes (e.g., treatment and care, quality of life, psychological well being, and health outcomes) in both groups.Research in context1.Systematic review: We searched PubMed for articles with the following search terms: dementia and screening; recognition; early or timely diagnosis; differential diagnosis; primary care; or diagnosis rate. In addition, we reviewed the reference lists of articles identified.2.Interpretation: We provided evidence that the screening of elderly patients for dementia in primary care practices can improve recognition of dementia considerably. However, there is a risk that patients receive a formal diagnosis of dementia based on a positive screening result (without further differential diagnostic assessment).3.Future directions: To reduce the risk of false-positive diagnoses, future studies should implement screening procedures that include further differential diagnostic. Future research needs to provide evidence that screening for dementia improves health outcomes for patients who are formally diagnosed with dementia after they have been screened positive for dementia.
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![Differential diagnoses of dementia in primary care patients formally diagnosed after they have screened positive for dementia (n = 72).](gr1){#fig1}

###### 

Sociodemographic and clinical characteristics of the study sample

  Variable                      Total sample (n = 146)   Formally diagnosed after screening   *t*            df     *P* value   
  ----------------------------- ------------------------ ------------------------------------ -------------- ------ ----------- ----------------------------------------------
  Female sex                    91 (62)                  38 (51)                              53 (74)        ---    ---         \<.01[∗](#tbl1fnlowast){ref-type="table-fn"}
  Age (y)                       79.58 ± 5.32             79.30 ± 4.98                         79.88 ±5.66    0.65   142.56      .51[†](#tbl1fndagger){ref-type="table-fn"}
  Living alone                  66 (45)                  31 (42)                              35 (49)        ---    ---         .51[∗](#tbl1fnlowast){ref-type="table-fn"}
  Cognitive impairment (MMSE)   23.14 ± 4.96             24.26 ± 4.83                         22.00 ± 4.87   2.81   145.81      \<.01[†](#tbl1fndagger){ref-type="table-fn"}
   None (score 27--30)          52 (37)                  35 (47)                              17 (24)                           \<.02[∗](#tbl1fnlowast){ref-type="table-fn"}
   Mild (score 20--26)          56 (38)                  24 (32)                              32 (44)                           
   Moderate (score 10--19)      32 (22)                  13 (18)                              19 (26)                           
   Severe (score 0--9)          6 (4)                    2 (3)                                4 (6)                             
  Depression (GDS ≥6)           36 (25)                  18 (24)                              18 (25)        ---    ---         1.00[∗](#tbl1fnlowast){ref-type="table-fn"}
  Functional status (B-ADL)     3.26 ± 2.23              2.73 ± 2.01                          3.80 ± 2.33    2.97   141.54      \<.01[†](#tbl1fndagger){ref-type="table-fn"}

Abbreviations: MMSE, Mini Mental State Examination (range 0--30; higher score indicates better cognitive functioning); B-ADL, Bayer Activities of Daily Living Scale (range 0--10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score 0--15; score ≥6 indicates depression).

NOTE. Data presented as n (%) or mean ± standard deviation.

Fisher\'s exact test.

Welch\'s *t* test.

###### 

Factors associated with receiving a formal diagnosis of dementia after screening

  Variable                      Formally diagnosed after screening   OR             *t*    *P* value   95% CI   
  ----------------------------- ------------------------------------ -------------- ------ ----------- -------- -------------
  Age (y)                       80.08 ± 5.35                         80.13 ± 5.15   0.92   0.85        .41      0.74--1.14
  Female sex                    17 (45)                              37 (77)        5.42   3.51        \<.01    1.93--15.22
  Living alone                  11 (29)                              25 (52)        1.02   0.03        .98      0.19--5.53
  Cognitive impairment (MMSE)   24.00 ± 5.28                         21.87 ± 4.63   0.93   1.23        .24      0.82--1.05
  Functional status (B-ADL)     2.97 ± 2.17                          3.68 ± 2.22    1.35   1.54        .15      0.89--2.04
  Depression (GDS)              10 (26)                              11 (23)        0.65   0.40        .69      0.07--6.42

Abbreviations: OR, odds ratio; CI, confidence interval; MMSE, Mini Mental State Examination (range 0--30; higher score indicates better cognitive functioning); B-ADL, Bayer Activities of Daily Living Scale (range 0--10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score 0--15; score ≥6 indicates depression).

NOTE. Data presented as mean ± standard deviation or n (%). Conditional fixed effect logistic regression analysis (n = 86 patients assigned to n = 15 clusters): F(6,14) = 3.68, *P* \< .05.
